Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study



Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnostic accuracy of the novel Fujifilm SILVAMP TB LAM (FujiLAM) assay with the WHO-recommended Alere Determine TB-LAM Ag test (AlereLAM) using urine samples from HIV-positive patients.


Reversing the neglect of children and adolescents affected by tuberculosis


Although tuberculosis is preventable and curable, it remains among the top ten causes of death in children younger than 5 years globally. More than 80% of children who die from tuberculosis are younger than 5 years, and 96% die without ever receiving appropriate care. Estimates from WHO indicate that in 2021, 1·2 million children (aged <10 years) and young adolescents (aged 10–14 years) developed tuberculosis, and 209 000 died from the disease. 

Experiences and perceptions of urine sampling for tuberculosis testing among HIV patients: a multisite qualitative descriptive study


Objectives Evidence on the acceptability of urine-based assays for tuberculosis (TB) diagnosis among patients remains limited. We sought to describe patients’ experiences and perceptions of urine sampling for TB testing at point of care.

Setting Study sites in Kenya, Uganda, Mozambique and South Africa.

Participants Adult ambulatory HIV patients enrolled in a TB diagnostic study were selected purposively.

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo